Similarly, another study demonstrated the prognostic value of RAD51 expression in non-small cell lung cancer (NSCLC) patients undergoing neoadjuvant chemotherapy, further establishing RAD51 as a robust biomarker in this context (25). Here, RAD51 is linked to non-small cell lung carcinoma.